AZN

Oncology and rare disease momentum offset cardiovascular headwinds.

Market Domination Overtime Host Jared Blikre keeps track of several stocks moving in extended-hours trading after releasing earnings results, including AstraZeneca (AZN), AbbVie (ABBV), and Kenvue (KVUE).

AstraZeneca Q3 earnings beat forecasts as the drugmaker launches a $1.5 billion savings plan to fund its AI-backed pipeline.

AstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its…

AstraZeneca reported third quarter 2026 results ahead of expectations, with revenue of US$16.21b, net income of US$3.12b and core EPS of US$2.79, and reaffirmed full year guidance for mid to high single digit revenue growth and low double digit core EPS…

Ultomiris, one of AstraZeneca’s blockbuster sellers in Q3, is currently approved across five rare disease indications.

AstraZeneca stock gapped higher Friday as cancer drugs Enhertu and Tagrisso lent themselves to a solid third-quarter report.

AstraZeneca Chief Financial Officer Aradhana Sarin says the drug company uses AI in almost every aspect of the work they do. She talks beating on earnings, their drug pipeline and how the company approaches dealmaking. She speaks on "Bloomberg Surveillance."

AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.

AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.